ARTICLE | Clinical News
Second Truvada/Sustiva combination fails
August 11, 2005 1:16 AM UTC
Gilead (GILD) fell $1.13 to $41.55 on Wednesday following Tuesday's post-market news that a second fixed-dose combination of HIV drugs Truvada emtricitabine/tenofovir from GILD and Sustiva efavirenz f...